Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study.
Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study.
复制标题
肝硬化门脉高压临床显着性放射组学特征的开发和验证 (CHESS1701)：一项前瞻性多中心研究
DOI：
10.1016/j.ebiom.2018.09.023
复制
发表时间：
2018-10
期刊：
影响因子：
11.1
通讯作者：
Qi X
中科院分区：
文献类型：
--
作者：
Liu F;Ning Z;Liu Y;Liu D;Tian J;Luo H;An W;Huang Y;Zou J;Liu C;Liu C;Wang L;Liu Z;Qi R;Zuo C;Zhang Q;Wang J;Zhao D;Duan Y;Peng B;Qi X;Zhang Y;Yang Y;Hou J;Dong J;Li Z;Ding H;Zhang Y;Qi X
临床上显著的门静脉高压症(CSPH)与食道静脉曲张和明显的临床失代偿风险增加有关。然而，肝静脉压力梯度(HVPG≥10 mm Hg)的金标准是有创性的，因此不适合常规的临床实践。本研究旨在开发和验证一种基于放射组学的模型，作为一种非侵入性的方法，用于准确检测肝硬变中的CSPH。这项前瞻性多中心诊断试验(CHESS1701，ClinicalTrials.gov标识符：NCT03138915)涉及2016年8月至2017年9月中国5个肝中心的385名肝硬化患者。收集在导尿术前14 内同时进行高压性胃电图测量和增强CT检查的患者。CSPH的非侵入性放射组学模型名为rHVPG，是基于连续222名患者的训练队列中的CT图像开发的，并在4个外部验证队列中对163名连续患者的诊断性能进行了前瞻性评估。RHVPG对CSPH的诊断效果较好，C指数为0.849(95%CI：0.786~0.911)。RHVPG在4个外部前瞻性验证队列中的应用仍表现优异，C指数分别为0·889(95%CI：0·752~1·000)、0·800(95%CI：0·614~0·986)、0·917(95%CI：0·772~1·000)和0·827(95%CI：0·618~1·000)。观察者间和观察者内一致性的组内相关系数分别为0.92-0.99和0.97-0.99。放射组学特征被开发出来，并被前瞻性地验证为无创检测肝硬变CSPH的准确方法。当无创伤性经颈静脉手术时，rHVPG评估工具可帮助快速识别CSPH。
Clinically significant portal hypertension (CSPH) is associated with an incremental risk of esophageal varices and overt clinical decompensations. However, hepatic venous pressure gradient (HVPG) measurement, the gold standard for defining CSPH (HVPG≥10 mm Hg) is invasive and therefore not suitable for routine clinical practice. This study aims to develop and validate a radiomics-based model as a noninvasive method for accurate detection of CSPH in cirrhosis. The prospective multicenter diagnostic trial (CHESS1701, ClinicalTrials.gov identifier: NCT03138915) involved 385 patients with cirrhosis from five liver centers in China between August 2016 and September 2017. Patients who had both HVPG measurement and contrast-enhanced CT within 14 days prior to the catheterization were collected. The noninvasive radiomics model, termed rHVPG for CSPH was developed based on CT images in a training cohort consisted of 222 consecutive patients and the diagnostic performance was prospectively assessed in 163 consecutive patients in four external validation cohorts. rHVPG showed a good performance in detection of CSPH with a C-index of 0·849 (95%CI: 0·786–0·911). Application of rHVPG in four external prospective validation cohorts still gave excellent performance with the C-index of 0·889 (95%CI: 0·752–1·000, 0·800 (95%CI: 0·614–0·986), 0·917 (95%CI: 0·772–1·000), and 0·827 (95%CI: 0·618–1·000), respectively. Intraclass correlation coefficients for inter- and intra-observer agreement were 0·92–0·99 and 0·97–0·99, respectively. A radiomics signature was developed and prospectively validated as an accurate method for noninvasive detection of CSPH in cirrhosis. The tool of rHVPG assessment can facilitate the identification of CSPH rapidly when invasive transjugular procedure is not available.
登录
查看更多内容
影响因子：
--
作者：
Gharib AM;Han MAT;Meissner EG;Kleiner DE;Zhao X;McLaughlin M;Matthews L;Rizvi B;Abd-Elmoniem KZ;Sinkus R;Levy E;Koh C;Myers RP;Subramanian GM;Kottilil S;Heller T;Kovacs JA;Morse CG
通讯作者：
Morse CG
放射组学特征：预测早期（I 期或 II 期）非小细胞肺癌无病生存的潜在生物标志物
影响因子：
19.7
作者：
Huang, Yanqi;Liu, Zaiyi;Liang, Changhong
通讯作者：
Liang, Changhong
影响因子：
13.5
作者：
Abraldes, Juan G.;Bureau, Christophe;Berzigotti, Annalisa
通讯作者：
Berzigotti, Annalisa
DOI：
10.1002/hep.29026
发表时间：
2017-03-01
期刊：
Hepatology (Baltimore, Md.)
影响因子：
--
作者：
Shung, Dennis L;Garcia-Tsao, Guadalupe
通讯作者：
Garcia-Tsao, Guadalupe
影响因子：
64.8
作者：
Esteva A;Kuprel B;Novoa RA;Ko J;Swetter SM;Blau HM;Thrun S
通讯作者：
Thrun S